Oncology Venture strikes diagnostics deal with Eisai
Oncology Venture has signed an agreement with the drug group Eisai for a companion diagnostic to identify the proper cancer patients to treat with a drug from the Japanese company.
BY LONNI LYNGE
The Denmark-based biotech company Oncology Venture, which is a spin off from Medical Prognosis Institute, ended last week by signing a partnership deal with Japan’s Eisai. This is according to a press release from the biotech.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Oncology Venture wins CE marking for diagnostic tool
For abonnenter
